title: High prevalence of thrombocytopenia in SLE patients with a high level of anticardiolipin antibodies combined with lupus anticoagulant.
abstract: The relationship between thrombocytopenia and the level of anticardiolipin antibodies (aCL) and/or the existence of lupus anticoagulant (LA) ware studied in 146 patients with systemic lupus erythematosus (SLE). These patients were divided into six groups: A, those LA positive with a high level of aCL (>10 U/ml) (10 cases); B, those LA positive with a low level of aCL (3-10 U/ml) (15 cases); C, those LA positive but aCL negative (<3 U/ml) (12 cases); D, LA negatives with a high level of aCL (12 cases); E, LA negatives with a low level of aCL (16 cases); and F, aCL and LA double negatives (81 cases). The prevalence of thrombocytopenia (platelet count < or = 100 x 10(9)L) was by far the highest in group A (9/10 cases, 90.0%, P < 0.005, Fisher's exact probability test) as compared with group B (4/15 cases, 26.7%), group C (4/12 cases, 33.3%), group D (1/12 cases, 8.3%), group E (4/16 cases, 25.5%), and group F (9/81 cases, 11.1%). When the relationship between moderate thrombocytopenia and arterial or venous thrombosis was studied in these patients with SLE, thrombocytopenia was detected in 10 (83.3%, P < 0.005, Fisher's exact probability test) of 12 patients with arterial thrombosis; however, it was present in only 4 (23.5%) of 17 patients with venous thrombosis and in 14 (12.3%) of 114 patients without thrombosis. These findings suggest that a high aCL activity combined with LA positively reflects a high risk for both thrombocytopenia and arterial thrombosis.
authors.affiliation: The Central Laboratory for Clinical Investigation, Osaka University Hospital, Suita, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Nojima
authors.forename: E
authors.initials: E
authors.lastname: Suehisa
authors.forename: H
authors.initials: H
authors.lastname: Kuratsune
authors.forename: T
authors.initials: T
authors.lastname: Machii
authors.forename: M
authors.initials: M
authors.lastname: Toku
authors.forename: H
authors.initials: H
authors.lastname: Tada
authors.forename: K
authors.initials: K
authors.lastname: Yamaguti
authors.forename: T
authors.initials: T
authors.lastname: Koike
authors.forename: Y
authors.initials: Y
authors.lastname: Kanakura
authors.forename: T
authors.initials: T
authors.lastname: Kitani
authors.forename: N
authors.initials: N
authors.lastname: Amino
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D017153:Antibodies, Anticardiolipin / Q000032:analysis*; D001158:Arteries; D005260:Female; D006801:Humans; D015994:Incidence; D016682:Lupus Coagulation Inhibitor / Q000032:analysis*; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012016:Reference Values; D013921:Thrombocytopenia / Q000453:epidemiology* / Q000209:etiology*; D013924:Thrombophlebitis / Q000209:etiology; D013927:Thrombosis / Q000209:etiology
chemical_list: D017153:Antibodies, Anticardiolipin; D016682:Lupus Coagulation Inhibitor